Related Experiment Video

Updated: Jun 6, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

792

The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential

Die Li1, Shiqi Hu1,2, Jiarong Ye1

  • 1Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.

International Journal of Molecular Sciences
|November 27, 2024
PubMed

Insights

Tumor drug resistance limits cancer treatment success. Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) drives this resistance, highlighting it as a key therapeutic target for improving chemotherapy efficacy.

Area of Science:

  • Molecular Oncology
  • Cancer Therapeutics
  • Epigenetics

Background:

  • Tumor resistance to therapy is a major cause of cancer treatment failure, necessitating strategies to overcome it.
  • Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is an m6A methylation reader involved in post-transcriptional RNA regulation.
  • IGF2BP2 is implicated in cancer initiation, progression, and critically, in the development of tumor drug resistance.

Purpose of the Study:

  • To comprehensively review the mechanisms through which IGF2BP2 contributes to cancer therapy resistance.
  • To identify IGF2BP2 as a potential target for enhancing the efficacy of chemotherapy.
  • To guide future research towards developing more effective cancer treatments.

Main Methods:

  • Literature review synthesizing current research on IGF2BP2 function in cancer.
  • Analysis of molecular mechanisms linking IGF2BP2 to drug resistance.
  • Discussion of therapeutic implications for targeting IGF2BP2.

Main Results:

  • IGF2BP2 plays a significant role in mediating resistance to various cancer therapies.
  • Understanding IGF2BP2's function in RNA methylation and its downstream effects is key to deciphering resistance pathways.
  • Targeting IGF2BP2 presents a promising strategy to re-sensitize tumors to chemotherapy.

Conclusions:

  • IGF2BP2 is a critical mediator of tumor drug resistance.
  • Elucidating IGF2BP2-driven resistance mechanisms is essential for improving cancer treatment outcomes.
  • Further research into targeting IGF2BP2 holds potential for developing more effective chemotherapies and improving patient quality of life.
Keywords:
IGF2BP2RNA modificationscancerdrug resistancem6A modification

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K